EUVIMEDOntdek EUVIMED
Open access · CC BY 4.0

Access to novel drugs and therapeutics for children and youth: Eliciting citizens' values to inform public funding decisions

Cindy L Gauvreau iD, Lisa Wight, Mathushan Subasri, Antonia Palmer, Robin Hayeems, Alysha Croker, Julia Abelson iD, Brent Fraser, Yvonne Bombard, Charlotte Moore Hepburn, Michael G Wilson, Avram Denburg

Health Expectations · 2023

DOI: 10.1111/hex.13697 ↗

At a glance

Journal article in Health Expectations, 2023. Written by Cindy L Gauvreau and 11 co-authors. Institution: Child Health Evaluative Sciences Program, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada. Major MEDLINE topics: Policy, Technology Assessment, Biomedical. Cited 7 times so far (Crossref); 64 references. The full text is freely available (open access, CC BY 4.0). Funded by: CIHR, McMaster University, Canadian Institutes of Health Research.

SamenvattingSubjectsBibliografische gegevensCiteRelated studies

Abstract (original language)

Introduction

The unique evidentiary, economic and ethical challenges associated with health technology assessment (HTA) of precision therapies limit access to novel drugs and therapeutics for children and youth, for whom such challenges are amplified. We elicited citizens' perspectives about values‐based criteria relevant to the assessment of paediatric precision therapies to inform the development of a child‐tailored HTA framework.

Methods

We held four citizen panels virtually in May–June 2021, informed by a plain‐language citizen brief summarizing global and local evidence about the challenges, policy and programmatic options and implementation strategies related to enhancing access to precision therapies for Canadian children and youth. Panellists were recruited through a nationally representative database, medical/patient networks and social media. We inductively coded and thematically analysed panel transcripts to generate themes and identify priority values.

Results

The perspectives of panellists ( n = 45) coalesced into four overlapping themes, with attendant subthemes, relevant to a child‐tailored HTA framework: (1) Childhood Distinctions: vulnerability, ‘fair innings’, future potential, family impacts; (2) Voice: agency of children and youth; lived versus no lived experience; (3) One versus Many: disease severity, rarity, equity, unmet need and (4) Health System Governance: funding, implementation inequities, effectiveness and safety. Participants broadly agreed that childhood distinctions, particularly family impacts, justify child‐tailored HTA. Dissent arose over whose voice should inform HTA and how such perspectives are best incorporated.

Conclusions

Citizens can offer unique insights into criteria relevant to the development or revision of HTA frameworks to capture holistic, societally responsive dimensions of value attached to unique contexts or populations, including children. Balancing the hopes and expectations of patients and caregivers for access to expensive but potential life‐altering therapies against the opportunity costs borne by encompassing health systems is a fundamental challenge that will require rigorous methods to elicit, weigh and reconcile varied views. Patient or Public Contribution A patient advocate served on the steering committee of this study and co‐authored this article. Key informants for the Citizen Brief included patient advocates and caregivers; a separate patient advocate reviewed the Brief before dissemination. Qualitative and quantitative data were collected from the general public and caregivers of children, with written consent.

Subjects

MeSH terms (MEDLINE)

PolicyTechnology Assessment, BiomedicalHumansAdolescentChildCanadaCosts and Cost Analysis

Author keywords

access to novel drugschildren and youthcitizens' valuesdeliberative public engagementhealth technology assessmentpublic funding decisions

Authors and institutions

  • Child Health Evaluative Sciences Program, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada.
  • Ac2orn: Advocacy for Canadian Childhood Oncology Research, Toronto, Ontario, Canada.
  • Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
  • Centre for Policy, Pediatrics and International Collaboration, Health Products and Food Branch, Health Canada, Ottawa, Ontario, Canada.
  • Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
  • Pharmaceutical Reviews, CADTH, Ottawa, Ontario, Canada.

ORCID profiles: Cindy L Gauvreau, Julia Abelson

Funding

  • CIHR
  • McMaster University
  • Canadian Institutes of Health Research
  • Pediatric Oncology Group of Ontario
  • Canadian Centre for Applied Research in Cancer Control

Cite

APA

Gauvreau, C. L., Wight, L., Subasri, M., Palmer, A., Hayeems, R., Croker, A., Abelson, J., Fraser, B., Bombard, Y., Moore Hepburn, C., Wilson, M. G., & Denburg, A. (2023). Access to novel drugs and therapeutics for children and youth: Eliciting citizens' values to inform public funding decisions. Health Expectations. https://doi.org/10.1111/hex.13697

Vancouver

Gauvreau CL, Wight L, Subasri M, Palmer A, Hayeems R, Croker A, et al. Access to novel drugs and therapeutics for children and youth: Eliciting citizens' values to inform public funding decisions. Health Expectations. 2023. doi:10.1111/hex.13697

BibTeX
@article{Gauvreau2023,
  author = {Gauvreau, Cindy L and Wight, Lisa and Subasri, Mathushan and Palmer, Antonia and Hayeems, Robin and Croker, Alysha and Abelson, Julia and Fraser, Brent and Bombard, Yvonne and Moore Hepburn, Charlotte and Wilson, Michael G and Denburg, Avram},
  title = {Access to novel drugs and therapeutics for children and youth: Eliciting citizens' values to inform public funding decisions},
  journal = {Health Expectations},
  year = {2023},
  doi = {10.1111/hex.13697}
}
Start for free →